Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totalling 4,660,000 shares, an increase of 230.5% from the November 30th total of 1,410,000 shares. Based on an average daily volume of 1,660,000 shares, the short-interest ratio is presently 2.8 days.

Trevi Therapeutics Stock Performance

Shares of TRVI stock traded up $0.13 on Friday, hitting $4.34. The company had a trading volume of 384,317 shares, compared to its average volume of 616,366. Trevi Therapeutics has a twelve month low of $1.27 and a twelve month high of $4.68. The firm has a market cap of $333.60 million, a P/E ratio of -9.86 and a beta of 0.96. The stock’s 50-day moving average is $3.18 and its two-hundred day moving average is $3.03.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the business earned ($0.08) EPS. Equities research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Trading of Trevi Therapeutics

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its position in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Trevi Therapeutics during the 2nd quarter worth approximately $61,000. Intech Investment Management LLC bought a new stake in shares of Trevi Therapeutics in the 3rd quarter valued at $63,000. The Manufacturers Life Insurance Company lifted its position in shares of Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after acquiring an additional 11,450 shares during the period. Finally, SG Americas Securities LLC bought a new position in Trevi Therapeutics during the third quarter worth $78,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TRVI shares. Leerink Partnrs upgraded Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Trevi Therapeutics in a report on Thursday, December 12th. B. Riley reissued a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Raymond James assumed coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They issued an “outperform” rating and a $9.00 target price for the company. Finally, Leerink Partners assumed coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target on the stock. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $9.31.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.